+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RAN GTPase as a target for cancer therapy: Ran binding proteins

RAN GTPase as a target for cancer therapy: Ran binding proteins

Current Molecular Medicine 11(8): 686-695

The identification of a relevant effector of Ran GTPase (Ran) signaling and its pathways could provide a novel approach to cancer therapeutics. With recent research highlighting the significant relationship between Ran expression and the occurrence and progression of cancer, the development of a small molecule compound that would decrease the endogenous levels of Ran in the cell would have anti-mitotic effects and could lead to the development of new types of cancer therapeutics. In the absence of Ran binding proteins, Ran is expected to remain locked up in non-productive complexes with importins and is effectively removed from the system. Thus, Ran binding proteins present as a logical molecular target for the inhibition of Ran signaling within the cancer cell. Moreover, this family of proteins has been shown to have various other functions within the cell, some of which are also anti-neoplastic. The purpose of this review is to discuss Ran binding proteins and how their pathways may be exploited to provide an effective cancer treatment.

(PDF emailed within 1 workday: $29.90)

Accession: 055333102

Download citation: RISBibTeXText

PMID: 21902650

Related references

GDP/GTP exchange factors or GTPase activating proteins for small GTP binding proteins regulated by heterotrimeric GTP binding proteins. Cell Structure & Function 26(5): 337, October, 2001

The Cdc42/Rac-interactive binding motif is required for Rop-specific GTPase activation by a novel family of Rho GTPase-activating proteins from Arabidopsis. Plant Biology (Rockville) : 36-37, 2000

Arabidopsis RopGAPs are a novel family of rho GTPase-activating proteins that require the Cdc42/Rac-interactive binding motif for rop-specific GTPase stimulation. Plant Physiology 124(4): 1625-1636, 2000

Characterization of the interactions between the small GTPase Cdc42 and its GTPase-activating proteins and putative effectors. Comparison of kinetic properties of Cdc42 binding to the Cdc42-interactive domains. Journal of Biological Chemistry 272(35): 21999-22007, 1997

Studies on the alpha-crystallin target protein binding sites: sequential binding with two target proteins. Molecular Vision 7: 114-119, 2001

DHA alters expression of target proteins of cancer therapy in chemotherapy resistant SW620 colon cancer cells. Nutrition and Cancer 62(5): 611-621, 2010

Magnesium fluoride-dependent binding of small G proteins to their GTPase-activating proteins. Biochemistry (American Chemical Society) 38(45): 981-7, 1999

GTPase activating proteins for the smg-21 GTP-binding protein having the same effector domain as the ras proteins in human platelets. Biochemical and Biophysical Research Communications 159(3): 1411-1419, 1989

Rac GTPase interacts with GAPs and target proteins through multiple effector sites. Embo Journal 14(21): 5297-5305, 1995

Targeting HER proteins in cancer therapy and the role of the non-target HER3. British Journal of Cancer 97(4): 453-457, 2007

Shifting of the penicillin binding proteins that are the target for inhibition by beta-lactams as a likely mechanism of resistance to antibiotics during therapy. Chemioterapia 4(1): 113-115, 1985

The SSX family of cancer-testis antigens as target proteins for tumor therapy. Clinical & Developmental Immunology 2010: 150591-150591, 2011

Heat shock proteins in ovarian cancer: a potential target for therapy. Gynecologic Oncology 119(1): 164-166, 2010